Skip to main content
lexblog.com/lib/S1MXPJXGviewrecordjson
{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI®",
    "url": "https://www.lexblog.com/2024/02/02/fdas-office-of-prescription-drug-promotion-issues-its-first-untitled-letter-of-the-year-to-novartis-for-misleading-statement-relating-to-kisqali-2/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-S1MXPJXG",
        "url": "https://www.lexblog.com/lib/S1MXPJXG/"
    },
    "datePublished": "2024-02-02T17:36:16-05:00",
    "dateModified": "2024-02-02T14:36:50-05:00",
    "author": {
        "@type": "Person",
        "name": "Dominick DiSabatino, Eve Costopoulos, Cortney Inman"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Sheppard, Mullin, Richter & Hampton LLP"
    },
    "organizationScope": "at-publication",
    "about": "Food, Drug & Agriculture",
    "sourceUrl": "https://www.fdalawblog.com/?p=2160",
    "sourceStability": "may-move"
}